CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 36 enrolled
Drug / intervention
Vigiis 101-LAB +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04088474
NCT04088474N/ACompleted

Functional Assessment in The Intestinal Flora Improvement

SunWay Biotech Co., LTD.·interventional·Posted Sep 12, 2019·Updated Sep 13, 2019

In Brief

A clinical study evaluating Vigiis 101-LAB and Placebo for Gastrointestinal Microbiome. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This clinical trial was conducted as part of the "Methods for Evaluating the Improvement of Gastrointestinal Function in Health Food" announced by the Department of Health, DOH (currently known as Ministry of Health and Welfare, MOHW) on the test article, "Vigiis 101-LAB powder (Capsules)", manufactured by SunWay Biotech Co., Ltd.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 12, 2019
Enrollment StartMar 5, 2016
Primary CompletionJul 6, 2016
Study CompletionDec 18, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.8 years ago

Interventions

Vigiis 101-LABdietary

examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)

Placebodietary

Maltodextrin was used as a placebo